MedTrace Logo

Anthocyanin Rich Extract (ACRE) in Patients With Ulcerative Colitis

NCT04000139 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-05-11

No results posted yet for this study

Summary

This study evaluates the efficacy and safety of a bilberry derived anthocyanin-rich extract in patients with ulcerative colitis. Two thirds of participants will receive the anthocyanin-rich extract, while one third will receive placebo, for 8 weeks of treatment.

Conditions

Interventions

DRUG

Standardized anthocyanin-rich extract

3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).

DRUG

Placebo

3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • The Broad Foundation

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Gerhard Rogler, Prof. Dr. med. Dr. phil. · Universitätsspital Zürich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-03-11
Completion
2021-03-11

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04000139 on ClinicalTrials.gov